DOACs Should Be Standard of Care in Cancer-Associated Thrombosis DOACs Should Be Standard of Care in Cancer-Associated Thrombosis
Direct oral anticoagulants are more effective than dalteparin in reducing the risk of thrombosis recurrence without significantly increasing the risk of major bleeding.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 21, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Supplements warning: The vitamin linked to a 22% increased risk of bleeding in the brain
DESPITE growing doubts about their safety, supplements remain massively popular in the UK. The risks associated with supplements generally occur at high doses, but prolonged use of some vitamins may also pose risks. One popular vitamin has been shown to increase the risk of haemorrhagic stroke by 22 percent, according to a study. (Source: Daily Express - Health)
Source: Daily Express - Health - January 17, 2022 Category: Consumer Health News Source Type: news

The Cornelian Dilemma of Quitting DAPT The Cornelian Dilemma of Quitting DAPT
A new study evaluating the safety of DAPT de-escalation to ticagrelor monotherapy in patients at high bleeding risk after PCI raises new questions in the field of antithrombotic therapy management.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 14, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Whole-spine MRI uncovers abusive head trauma injuries in children
Performing MRI of the whole spine in young children thought to be victims o...Read more on AuntMinnie.comRelated Reading: Can black bone MRI match CT for pediatric head trauma? New statement defines abusive head trauma in kids Postmortem imaging can reveal hidden trauma missed in autopsy Abused children often have spinal bleeding (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 13, 2022 Category: Radiology Source Type: news

Early outcomes of pelvic trauma patients - complications, ICU stay and treatment concepts in two ATLS compliant trauma centers: Germany and Qatar - Keil H, El-Menyar A, Daerr J, Weil F, Abdelrahman H, Alhammoud A, Ghouri SI, Babikir E, Wahlen BM, Al-Thani H, Gruetzner PA, Muenzberg M.
PURPOSE OF THE STUDY Pelvic trauma causes severe threats especially to polytraumatized patients. Not only it is in itself a possible cause for significant bleeding, but it also indicates a high risk for intra-abdominal injuries. The initial treatment of pa... (Source: SafetyLit)
Source: SafetyLit - January 12, 2022 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Medicare Seeks To Limit Coverage For Controversial Alzheimer ’s Drug Aduhelm
Doctors demanded the FDA revoke its approval for the Alzheimer ’s drug Aduhelm, which can cause side effects like brain bleeding. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 11, 2022 Category: Pharmaceuticals Authors: Zachary Snowdon Smith, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news Source Type: news

Pot Use Raises Risks After Severe Form of Stroke
FRIDAY, Jan. 7, 2022 -- If you have any risk factors for stroke and you like to smoke pot, a new study suggests you should stop toking. Researchers found that people with an aneurysmal subarachnoid hemorrhage, a rare, severe type of bleeding... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 7, 2022 Category: General Medicine Source Type: news

Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States
NEW BRUNSWICK, N.J., January 6, 2022 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States (U.S.), showing that a single shot of the Johnson & Johnson COVID-19 vaccine resulted in long-lasting protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions. The study was sponsored by the Janssen Pharmaceutical Companies of Johnson & Johnson and conducted in partnership with the Department of Science-Aetion, Inc, and the Division...
Source: Johnson and Johnson - January 6, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Bleeding After Reperfusion Contributes to Cardiac Injury in MI Bleeding After Reperfusion Contributes to Cardiac Injury in MI
Intramyocardial hemorrhage could be a major cause of reperfusion injury after MI and contribute to myocardial damage, a new study has found, giving new leads for therapeutic intervention.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 6, 2022 Category: Cardiology Tags: Cardiology News Source Type: news

Dr. Kirsten Watson Alcorn: 'Blood donation is absolutely vital, and it only comes from other human beings'
"Many medical conditions involve treatments that are only possible because transfusion is available as part of the treatment plan, from hemorrhage (such as trauma or obstetrical bleeding) to cancer care and organ transplants," Dr. Kirsten Watson Alcorn said. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 30, 2021 Category: American Health Authors: Natalie Guevara Source Type: news

Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant
NEW BRUNSWICK, N.J., December 30, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced new preliminary results from the South African Phase 3b Sisonke study which showed that a homologous (same vaccine) booster shot of the Johnson & Johnson COVID-19 vaccine (Ad26.COV2.S) demonstrated 85 percent effectiveness against COVID-19-related hospitalization. The study, conducted by the South African Medical Research Council (SAMRC), showed that the Johnson & Johnson booster reduced the risk of hospitalization from COVID-19 among healthcare workers in South Africa after Omicron became the dominant var...
Source: Johnson and Johnson - December 30, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Untreated Infection Can Double Bleed Risk in Anticoagulant Users Untreated Infection Can Double Bleed Risk in Anticoagulant Users
In patients taking oral anticoagulants, an untreated community-acquired respiratory tract infection is associated with a twofold greater risk of bleeding in the 2 weeks following infection, a case series showed.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 29, 2021 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Year in Review: Bay Area fed its drug habit with FDA approvals
No blockbusters, but the Bay Area's drug-development engine continued to produce a wide range of therapeutics in 2021. From a drug-implant developed by Genentech Inc. of South San Francisco for people with the eye disease wet age-related macular degeneration to San Mateo-based Myovant Sciences Ltd.'s treatment for women with heavy menstrual bleeding due to severe uterine fibroids, biotech and traditional drug deve lopers continued a long streak of Food and Drug Administration approvals. This slideshow… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 29, 2021 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Year in Review: Bay Area fed its drug habit with FDA approvals
No blockbusters, but the Bay Area's drug-development engine continued to produce a wide range of therapeutics in 2021. From a drug-implant developed by Genentech Inc. of South San Francisco for people with the eye disease wet age-related macular degeneration to San Mateo-based Myovant Sciences Ltd.'s treatment for women with heavy menstrual bleeding due to severe uterine fibroids, biotech and traditional drug deve lopers continued a long streak of Food and Drug Administration approvals. This slideshow… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 28, 2021 Category: Health Management Authors: Ron Leuty Source Type: news

Risk analysis of factors in clinical anxiety among undergraduate and postgraduate students in dentistry
This study aimed to determine the level of anxiety along with anxiety-provoking factors among clinical dental students. Methods: This study included dental undergraduate and postgraduate clinical students from a public university. A modified version of the self-administered Moss and McManus questionnaire, which consisted of 50 items, was utilized to evaluate the levels of anxiety. The results were analyzed using SPSS ® version 24. The significance level was set at p
Source: Dental Technology Blog - December 23, 2021 Category: Dentistry Source Type: news

New Approaches to Hemophilia Treatment:'Our Cup Runneth Over'New Approaches to Hemophilia Treatment:'Our Cup Runneth Over '
New approaches to treating hemophilia may soon replace the decades-old approach of using factor concentrates to control bleeding in patients with hemophilia A and hemophilia B.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 22, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease w...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Uterine artery embolization underused for postpartum bleeding
Uterine artery embolization (UAE) is underused despite being a better optio...Read more on AuntMinnie.comRelated Reading: Is uterine artery embolization underused for postpartum bleeding? Can machine-learning models predict IR outcomes? Prostatic artery embolization gains clinical momentum Study finds low reintervention rate for UAE of fibroids Online patient info about UAE could be better (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 20, 2021 Category: Radiology Source Type: news

Rivaroxaban Safely Cuts VTE Risk After COVID-19 Hospitalization Rivaroxaban Safely Cuts VTE Risk After COVID-19 Hospitalization
A randomized, open-label trial showed improved clinical outcomes from a low dose of direct oral anticoagulant in patients at high risk for venous thromboembolism and low risk for bleeding.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 17, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Johnson & Johnson Statement on its COVID-19 Vaccine Following CDC ACIP Meeting
NEW BRUNSWICK, N.J., December 16, 2021 – Johnson & Johnson remains confident in the overall positive benefit-risk profile of its COVID-19 vaccine. Studies have shown that the Johnson & Johnson COVID-19 vaccine generates strong antibody and cellular immune responses [i] and long-lasting immune memory[ii] and breadth of protection across variants. In addition, a growing body of evidence is revealing the strength of protection of our vaccine as a booster to either the Janssen COVID-19 vaccine or a different authorized or approved COVID-19 vaccine, both in terms of its efficacy and durability.[iii], [iv], [v], [v...
Source: Johnson and Johnson - December 16, 2021 Category: Pharmaceuticals Source Type: news

CDC Panel Backs mRNA COVID Vaccines Over J & J Due to Clot Risk
The CDC panel voted unanimously to prefer the Pfizer and Moderna vaccines after hearing a safety update on cases of thrombosis with thrombocytopenia syndrome, a condition that causes large clots that deplete the blood of platelets, resulting in uncontrolled bleeding. (Source: WebMD Health)
Source: WebMD Health - December 16, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
NEW BRUNSWICK, N.J., December 15, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company’s COVID-19 vaccine as a booster for adults aged 18 and older at least two months after primary vaccination with a single-shot of the Johnson & Johnson COVID-19 vaccine, and as a ‘mix and match’ booster following primary vaccination with an approved two-shot mRNA COVID-19 vaccine regimen (known as heterologous boosting). “We are pleased wi...
Source: Johnson and Johnson - December 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Nigeria: Poor Knowledge and Practice Around Oxytocin Could Put Women in Nigeria At Risk During Childbirth
[The Conversation Africa] Severe bleeding after childbirth - postpartum haemorrhage - is a leading cause of maternal morbidity and mortality in middle-income countries. Oxytocin is an affordable and effective drug that's recommended to prevent postpartum haemorrhage. (Source: AllAfrica News: Pregnancy and Childbirth)
Source: AllAfrica News: Pregnancy and Childbirth - December 14, 2021 Category: OBGYN Source Type: news

Cameroon: Big Steps Forward - Cameroon's Multi-Sector Approach to Reducing Pregnancy-Related Deaths
[Nigeria Health Watch] Jean Firwa and his wife Martha were excited to be expecting a baby after 10 years of trying to conceive. However, neither realised that their joy would be short-lived. On the morning of May 15, 2015, tragedy struck for the couple. Experiencing sharp pains, Martha needed to be transported to a hospital. With the closest hospital being 35 miles away, it was a struggle to transport her from Zanyao to the hospital in Yagoua, Mayo Danay Division, in the far North of Cameroon. "She was bleeding and there was no (Source: AllAfrica News: Pregnancy and Childbirth)
Source: AllAfrica News: Pregnancy and Childbirth - December 14, 2021 Category: OBGYN Source Type: news

New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from two studies evaluating the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) as a potential fixed-duration treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These data were both featured today during the American Society of Hematology (ASH) 2021 Annual Meeting. New secondary endpoint data from the Phase 3 GLOW study (NCT03462719) showed that fixed-duration treatment with I+V resulted in undetecta...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Experts Debate Aspirin for Primary Prevention in Type 2 Diabetes Experts Debate Aspirin for Primary Prevention in Type 2 Diabetes
At IDF 2021, two speakers presented different views on the benefit-risk balance of cardiovascular protection versus bleeding risk in those who haven't already had a vascular event.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 10, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

World Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster
NEW BRUNSWICK, N.J., December 9, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the interim recommendation by the Strategic Advisory Group of Experts on Immunization (SAGE) for the World Health Organization (WHO) supporting the use of the Johnson & Johnson COVID-19 vaccine as a booster shot in persons aged 18 years and above. The WHO recommend the booster shot should be administered two to six months after the primary vaccination. SAGE advises WHO on global vaccine and immunization policies, and its recommendations provide guidance on the use of vaccines supplied through the COVAX Facility...
Source: Johnson and Johnson - December 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Daunte Wright's girlfriend tried to stop his bleeding with a belt as he gasped for air, she testified at ex-officer Kim Potter's...
The passenger in Daunte Wright's car when he was killed was the "only one out of everybody there that was trying to help him," the young woman testified Thursday in the trial of the then-officer... #kimpotter #dauntewright #manslaughtertrial #trafficstop #thenofficer (Source: Reuters: Health)
Source: Reuters: Health - December 9, 2021 Category: Consumer Health News Source Type: news

Clinical Trials Lead to Promising Updates in Mesothelioma Immunotherapy
This study recruited patients with unresectable pleural mesothelioma who had not received prior chemotherapy. The primary endpoint of median overall survival was significantly longer with the addition of bevacizumab to chemotherapy at 18.8 months versus 16.1 months with chemotherapy alone. However, adverse events such as hypertension and bleeding were more common in the bevacizumab group. More recently, studies such as the phase II RAMSES trial in 2020 have shown promising results for combining anti-VEGF medication with chemotherapy as a second-line treatment. The addition of the VEGF inhibitor ramucirumab significan...
Source: Asbestos and Mesothelioma News - December 8, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Hemostatic Powder Noninferior in Nonvariceal Upper GI Bleeds Hemostatic Powder Noninferior in Nonvariceal Upper GI Bleeds
TC-325 hemostatic powder compares well with standard endoscopic treatment of acute nonvariceal gastrointestinal bleeding in a new study.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 8, 2021 Category: Surgery Tags: Gastroenterology News Source Type: news

A wearable microwave instrument can detect and monitor traumatic abdominal injuries in a porcine model - Candefjord S, Nguyen L, Buendia R, Oropeza-Moe M, Andersen NG, Fhager A, Persson M, Elam M, Oveland NP.
Abdominal injury is a frequent cause of death for trauma patients, and early recognition is essential to limit fatalities. There is a need for a wearable sensor system for prehospital settings that can detect and monitor bleeding in the abdomen (hemoperito... (Source: SafetyLit)
Source: SafetyLit - December 6, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses
NEW BRUNSWICK, N.J., DECEMBER 5, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch, M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center (BIDMC), which showed that a booster shot of the Johnson & Johnson COVID-19 vaccine (Ad26.COV2.S), administered at six months after a two-dose primary regimen of BNT162b2, increased both antibody and T-cell responses. These results demonstrate the potential benefits of heterologous boosting (mix-and-match...
Source: Johnson and Johnson - December 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Complete traumatic luxation of the eyeball - Singh M, Jassi AS, Kaur M, Gupta P.
PURPOSE: To report the computed tomography features of a case with complete luxation of the globe after a road traffic accident. CASE REPORT: A 35-year-old male presented with pain, loss of vision, and bleeding from the left eye 48 hr after a road traffic ... (Source: SafetyLit)
Source: SafetyLit - December 1, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Certain Blood Thinners Can Raise Risk of'Delayed' Bleeding After Head Injury
Title: Certain Blood Thinners Can Raise Risk of'Delayed'Bleeding After Head InjuryCategory: Health NewsCreated: 11/30/2021 12:00:00 AMLast Editorial Review: 12/1/2021 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - December 1, 2021 Category: Cardiology Source Type: news

Head trauma patients on older blood thinners face higher risk
Adults who are on older blood-thinning medications have a significantly highe...Read more on AuntMinnie.comRelated Reading: CT radiomics helps predict spontaneous intracerebral hemorrhage How well can AI software spot intracranial bleeding on head CT? Ultrasound detects astronaut's blood clot in space 5 risk factors help predict brain hemorrhage on CT (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 30, 2021 Category: Radiology Source Type: news

High blood pressure: Bleeding may signal dangerously high levels - what to spot
HIGH blood pressure is a tricky condition to keep on top of but blood secreting from a certain body part has been declared an early warning sign of extremely high and dangerous levels. (Source: Daily Express - Health)
Source: Daily Express - Health - November 30, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson to Evaluate Its COVID-19 Vaccine Against New Omicron COVID-19 Variant
Since the emergence of the COVID-19 pandemic, Johnson & Johnson (the Company) has been closely monitoring newly emerging COVID-19 variants. In collaboration with academic groups in South Africa and around the world, the Company has been evaluating the effectiveness of its COVID-19 vaccine across variants, including now the new and rapidly spreading Omicron variant. The Company is testing blood serum from participants in completed and ongoing booster studies to look for neutralizing activity against the Omicron variant. In addition, the Company is pursuing an Omicron-specific variant vaccine and will progress it as need...
Source: Johnson and Johnson - November 29, 2021 Category: Pharmaceuticals Source Type: news

Hormone therapy could prevent thousands of miscarriages each year in Britain, new NHS guidance says
Britain's health watchdog has approved the drug progesterone for expectant mothers who have previously had a miscarriage and are experiencing spotting or bleeding. (Source: the Mail online | Health)
Source: the Mail online | Health - November 24, 2021 Category: Consumer Health News Source Type: news

Health Worker Training Helps More Sick Newborns Survive in Uganda
By Irene Mirembe, Knowledge management manager, IntraHealth International A baby is measured for size at the Busowobi Health Center in Iganga District, Uganda. Photo by Tommy Trenchard for IntraHealth International.November 23, 2021When 25-year-old Aida Adongo started bleeding during her seventh month of pregnancy, she knew she had to seek care quickly. By the time she reached the Lwala Hospital, the nearest health facility in her community, she had already delivered one twin. The other was born safely at the hospital, thanks to the swift response of the medical team when she arrived.In Uganda, preterm births—bab...
Source: IntraHealth International - November 23, 2021 Category: International Medicine & Public Health Authors: kseaton Tags: Family Planning & Reproductive Health Maternal, Newborn, Child Health Education Performance Health workforce development Source Type: news

Long-term Risk of Upper GI Bleeding After H. Pylori Eradication Long-term Risk of Upper GI Bleeding After H. Pylori Eradication
This study aimed to determine the long-term real-world benefits of H. pylori eradication in preventing non-variceal upper GI bleeding, stratified by age group.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 23, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Concerns Grow Over Safety of Aduhelm After Death of Patient Who Got the Drug
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer ’s drug experienced brain bleeding or swelling, though many cases were asymptomatic. (Source: NYT Health)
Source: NYT Health - November 22, 2021 Category: Consumer Health News Authors: Pam Belluck Tags: your-feed-science Drugs (Pharmaceuticals) Clinical Trials Aduhelm (Drug) Alzheimer ' s Disease Labeling and Labels (Product) Brain Elderly Deaths (Fatalities) Biogen Inc Food and Drug Administration JAMA Neurology (Journal) RBC Source Type: news

Magnet ingestion knows no borders: A threat for Latin American children - Falcon AC, Fern ández-Valdes L, Iglesias C, Saps M.
INTRODUCTION AND AIMS: The ingestion of foreign bodies, such as magnets, is a potentially lethal accident that affects children and is associated with bleeding and gastrointestinal perforation, as well as death. There are no Latin American reports in the l... (Source: SafetyLit)
Source: SafetyLit - November 22, 2021 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

£2 jab could save thousands of trauma patients from bleeding to death
A cheap drug called tranexamic acid, or TXA, could save a third of people suffering major blood loss, and has no side effects. (Source: the Mail online | Health)
Source: the Mail online | Health - November 20, 2021 Category: Consumer Health News Source Type: news

Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news

Shotgun caused gaping hole in Arbery's chest, heavy bleeding
BRUNSWICK, Ga. — The shotgun blasts that hit Ahmaud Arbery punched a gaping hole in his chest and unleashed massive bleeding, a medical examiner testified Tuesday as jurors saw autopsy photos... #autopsyphotos #shotgun #ahmaudarbery #examiner #tshirt #jurors (Source: Reuters: Health)
Source: Reuters: Health - November 16, 2021 Category: Consumer Health News Source Type: news

Oral Factor XIa Inhibitor Cuts Post-Op VTE Risk: AXIOMATIC-TKR Oral Factor XIa Inhibitor Cuts Post-Op VTE Risk: AXIOMATIC-TKR
Milvexian shows promise as a new oral anticoagulant, but observers say more data are needed to confirm a bleeding advantage with this emerging class of drugs.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 15, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
This study establishes proof-of-principle for milvexian as a differentiated antithrombotic agent,” said Jeffrey Weitz, M.D., Professor of Medicine & Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute.[i] “Furthermore, the consistently low rates of bleeding across a 16-fold range of milvexian doses suggest that it has a wide therapeutic window, which opens the opportunity to explore milvexian across a broad range of patients including those for whom factor Xa inhibitors are underutilized or not indicated.” The tria...
Source: Johnson and Johnson - November 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

What Are Some Indications for a Vesicostomy?
Discussion A cutaneous vesicostomy is an incontinent diversion of the bladder to the external abdominal wall usually below the umbilicus that maintains a low-pressure urinary system. The urine drains into a collecting bag or hygiene product such as a diaper. It is usually used as a temporary diversion until bladder function resolves or another treatment can be carried out. However, it can also be used as a permanent diversion in some cases. A vesico-cutaneous fistula is similar but performed slightly differently. It is often intended to be a longer-term diversion procedure and is a continent diversion of the bladder. Some ...
Source: PediatricEducation.org - November 15, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

CABG Safe 3 Days After Stopping Ticagrelor: RAPID CABG CABG Safe 3 Days After Stopping Ticagrelor: RAPID CABG
A new randomized trial showed similar rates of severe bleeding in patients going to surgery at 3 days and 6 days after stopping the antiplatelet medication.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

Biogen ’s Controversial Alzheimer’s Drug Was Connected to a Patient Death, Just As the Company Presented Its Final Study Data
To say that Biogen’s Alzheimer’s drug aduhelm is controversial wouldn’t do its rocky road to approval justice. To say it’s complicated is even less satisfying, given that the studies leading to its approval were started, stopped and started again. Add to that reports of questionable meetings between the drug company’s scientists from Biogen and Food and Drug Administration (FDA) officials that led to an ongoing FDA investigation of the drug’s approval, and it’s understandable that the drug that was supposed to change the way Alzheimer’s is treated hasn’t exactly taken t...
Source: TIME: Health - November 12, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news